JAK-STAT途径mRNA在肾癌的表达及临床意义

The expression and clinical significance of JAK-STAT pathway mRNA in human re- nal cell carcinoma

目的研究JAK-STAT途径mRNA在人肾透明细胞癌的表达状况及其临床意义。方法收集人肾细胞癌组织标本20例,良性肾脏组织标本10例。采用RT-PCR的方法测定组织内JAK-STAT信号途经相关基因IFNAR、TYK2、JAK1、STAT1、STAT1、STAT2mRNA的相对表达量,比较肾癌组织和良性肾组织内表达量的差异。结果肾癌组织中JAK1和STAT1相对表达量分别为0.697±0.122和0.333±0.078;良性肾组织内的表达量为0.957±0.103和0.547±0.082。JAK1和STAT1mRNA相对表达量显著低于良性肾脏组织(P<0.05)。IFNAR、TYK2、JAK1和STAT2mRNA相对表达量与良性肾脏组织无显著差异。结论肾癌组织JAK1和STAT1mRNA的表达量降低可能是导致干扰素抵抗的潜在原因。

Objective To investigate the expression and clinical significance of JAK STAT pathway mRNA in human renal clear cell carcinoma. Methods A number of 20 cases of renal cell carcinoma samples and 10 cases of benign renal samples were collected. The relative expression of JAK STAT pathway genes known as IFNAR, TYK2, JAK1, STAT1, STAT1 and STAT2 were detected by RT PCR. Results The relative expressions of JAK1 and STAT1 in renal cell carcinoma and benign renal tissues were （0.697±0.122, 0.333±0.078）, and （0.957±0.103, 0.547±0.082）, which were significantly lower in the benign renal tissue （P〈0.05）. There was no significant difference between renal cell carcinoma and benign renal tissue in expression of IFNAR, TYK2, JAK1 and STAT2. Conclusion The resistance of renal cell carcinoma to interferon therapy might associate with the low expression levels of JAK1 and STAT1.